Pegvaliase

CHEMBL4297802 Phase 4 Zugelassen Enzyme
Half-Life
Bioavailability
Protein Binding
Molecular Weight
318.4 g/mol
LogP
-2.3
Phase
4

This enzyme therapy treats phenylketonuria (PKU) by providing a functional enzyme to lower phenylalanine levels.

Molekularmasse

318,4100 g/mol

LogP

-2,30

TPSA

111,00 Ų

Lipinski-Regel der Fünf

Bestanden

Pharmacokinetics (PK)

Pharmacodynamics (PD)

SMILES

COCCOCCCCCC(=O)NCCCC[C@@H](C(=O)O)N

InChI

InChI=1S/C15H30N2O5/c1-21-11-12-22-10-6-2-3-8-14(18)17-9-5-4-7-13(16)15(19)20/h13H,2-12,16H2,1H3,(H,17,18)(H,19,20)/t13-/m0/s1

Molecular Formula

C15H30N2O5

HBD / HBA

3 / 6

Rotierbare Bindungen

15

Schwere Atome

22

No targets recorded

Target interaction data is not yet available for this drug.

No interactions recorded

Drug interaction data is not yet available for this compound.

No side effects recorded

Side effect data is not yet available for this drug.

Häufig gestellte Fragen

This enzyme therapy treats phenylketonuria (PKU) by providing a functional enzyme to lower phenylalanine levels.

Yes, Pegvaliase is an approved drug. It has reached clinical phase 4. It is classified as a Enzyme.

{# References & Data Sources section for drug detail pages. Renders standard pharmacological database links plus the drug's data_sources field. #}

References & Data Sources

  • ChEMBL — European Bioinformatics Institute (EBI). CHEMBL4297802. Open-access bioactivity database.
  • PubChem — National Center for Biotechnology Information (NCBI). CID 86278362. Chemical information database.

Data aggregated from publicly available pharmacological databases. Last updated 2026-03-28.

Medizinischer Haftungsausschluss

This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.

Data sources: ChEMBL, PubChem, DailyMed.